Adenovirus Vaccine

Adenovirus Vaccine Comprehensive Study by Type (Type 4 Vaccine, Type 7 Vaccine), Application (Research & Academic Laboratories, Pharmaceutical & Biotechnology Companies, Others) Players and Region - Global Market Outlook to 2028

Adenovirus Vaccine Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Adenovirus vaccine contains live adenovirus Type 4 and Type 7. Adenovirus vaccine comes as two tablets, taken orally (by mouth) at the same time. The tablets should be swallowed whole, not chewed or crushed. The vaccine is approved for military personnel 17 through 50 years of age. It is recommended by the Department of Defense for military recruits entering basic training. It may also be recommended for other military personnel at high risk for adenovirus infection.This growth is primarily driven by Growing Demand due to Use in Cancer Gene Therapies.

AttributesDetails
Study Period2018-2028
Base Year2022
Forecast Period2023-2028
Volume UnitK Units
Value UnitUSD (Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


The Pharmaceuticals sector in the region has been increasing at a sustainable rate and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as Teva Pharmaceuticals (Isreal), Barr Labs (United States), Wyeth Laboratories (United States), Batavia Biosciences B.V. (The Netherlands), BAVARIAN NORDIC (Denmark), AlphaVax, Inc. (United States), BioNTech (Germany), INOVIO (United States), Cansino Biologics (China) and Moderna (United States), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Leading key players are focusing on strategic partnerships to improve their products and services. Companies are focusing on the approval of drugs and ongoing research and development.

Influencing Trend:
High Demand due to Use in use in Military Populations at Risk of Developing ARD from Adenoviruses and Increasing Demand from Pharmaceuticals Companies

Market Growth Drivers:
Growing Demand due to Use in Cancer Gene Therapies

Challenges:
The Stringent Government Regulation for Drug Approval

Restraints:
The Adverse Reaction for Pneumonia and Inflammation of the Stomach or Intestines

Opportunities:
Increasing Demand due to On-Going Research and Development

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mainly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the market's growth. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Data Sources of Adenovirus Vaccine Market Study

Primary Collection: InMail, LinkedIn Groups, Survey Monkey, Google, and Other professional Forums are some of the mediums utilized to gather primary data through key industry participants and appointees, subject-matter experts, C-level executives of Adenovirus Vaccine Industry, among others including independent industry consultants, experts, to obtain and verify critical qualitative commentary and opinion and quantitative statistics, to assess future market prospects.

The primary interviews and data collected as per the below protocols:
• By Designation: C-Level, D-Level, Others
• By Company Type: Tier 1, Tier 2, Tier 3

Secondary Data Sources such as Annual reports, Press releases, Analyst meetings, Conference calls, Investor presentations, Management statements, and SEC filings of Adenovirus Vaccine players along with Regulatory Sites, Association, World bank, etc were used as sources secondary set of data.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Adenovirus Vaccine Study Sheds Light on
— The Adenovirus Vaccine Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Adenovirus Vaccine industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Adenovirus Vaccine industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Type 4 Vaccine
  • Type 7 Vaccine
By Application
  • Research & Academic Laboratories
  • Pharmaceutical & Biotechnology Companies
  • Others
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Demand due to Use in Cancer Gene Therapies
    • 3.3. Market Challenges
      • 3.3.1. The Stringent Government Regulation for Drug Approval
    • 3.4. Market Trends
      • 3.4.1. High Demand due to Use in use in Military Populations at Risk of Developing ARD from Adenoviruses
      • 3.4.2. Increasing Demand from Pharmaceuticals Companies
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Adenovirus Vaccine, by Type, Application and Region (value, volume and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Adenovirus Vaccine (Value)
      • 5.2.1. Global Adenovirus Vaccine by: Type (Value)
        • 5.2.1.1. Type 4 Vaccine
        • 5.2.1.2. Type 7 Vaccine
      • 5.2.2. Global Adenovirus Vaccine by: Application (Value)
        • 5.2.2.1. Research & Academic Laboratories
        • 5.2.2.2. Pharmaceutical & Biotechnology Companies
        • 5.2.2.3. Others
      • 5.2.3. Global Adenovirus Vaccine Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Adenovirus Vaccine (Volume)
      • 5.3.1. Global Adenovirus Vaccine by: Type (Volume)
        • 5.3.1.1. Type 4 Vaccine
        • 5.3.1.2. Type 7 Vaccine
      • 5.3.2. Global Adenovirus Vaccine by: Application (Volume)
        • 5.3.2.1. Research & Academic Laboratories
        • 5.3.2.2. Pharmaceutical & Biotechnology Companies
        • 5.3.2.3. Others
      • 5.3.3. Global Adenovirus Vaccine Region
        • 5.3.3.1. South America
          • 5.3.3.1.1. Brazil
          • 5.3.3.1.2. Argentina
          • 5.3.3.1.3. Rest of South America
        • 5.3.3.2. Asia Pacific
          • 5.3.3.2.1. China
          • 5.3.3.2.2. Japan
          • 5.3.3.2.3. India
          • 5.3.3.2.4. South Korea
          • 5.3.3.2.5. Taiwan
          • 5.3.3.2.6. Australia
          • 5.3.3.2.7. Rest of Asia-Pacific
        • 5.3.3.3. Europe
          • 5.3.3.3.1. Germany
          • 5.3.3.3.2. France
          • 5.3.3.3.3. Italy
          • 5.3.3.3.4. United Kingdom
          • 5.3.3.3.5. Netherlands
          • 5.3.3.3.6. Rest of Europe
        • 5.3.3.4. MEA
          • 5.3.3.4.1. Middle East
          • 5.3.3.4.2. Africa
        • 5.3.3.5. North America
          • 5.3.3.5.1. United States
          • 5.3.3.5.2. Canada
          • 5.3.3.5.3. Mexico
    • 5.4. Global Adenovirus Vaccine (Price)
      • 5.4.1. Global Adenovirus Vaccine by: Type (Price)
  • 6. Adenovirus Vaccine: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Teva Pharmaceuticals (Isreal)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Barr Labs (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Wyeth Laboratories (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Batavia Biosciences B.V. (The Netherlands)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. BAVARIAN NORDIC (Denmark)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. AlphaVax, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. BioNTech (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. INOVIO (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Cansino Biologics (China)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Moderna (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Adenovirus Vaccine Sale, by Type, Application and Region (value, volume and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Adenovirus Vaccine (Value)
      • 7.2.1. Global Adenovirus Vaccine by: Type (Value)
        • 7.2.1.1. Type 4 Vaccine
        • 7.2.1.2. Type 7 Vaccine
      • 7.2.2. Global Adenovirus Vaccine by: Application (Value)
        • 7.2.2.1. Research & Academic Laboratories
        • 7.2.2.2. Pharmaceutical & Biotechnology Companies
        • 7.2.2.3. Others
      • 7.2.3. Global Adenovirus Vaccine Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Adenovirus Vaccine (Volume)
      • 7.3.1. Global Adenovirus Vaccine by: Type (Volume)
        • 7.3.1.1. Type 4 Vaccine
        • 7.3.1.2. Type 7 Vaccine
      • 7.3.2. Global Adenovirus Vaccine by: Application (Volume)
        • 7.3.2.1. Research & Academic Laboratories
        • 7.3.2.2. Pharmaceutical & Biotechnology Companies
        • 7.3.2.3. Others
      • 7.3.3. Global Adenovirus Vaccine Region
        • 7.3.3.1. South America
          • 7.3.3.1.1. Brazil
          • 7.3.3.1.2. Argentina
          • 7.3.3.1.3. Rest of South America
        • 7.3.3.2. Asia Pacific
          • 7.3.3.2.1. China
          • 7.3.3.2.2. Japan
          • 7.3.3.2.3. India
          • 7.3.3.2.4. South Korea
          • 7.3.3.2.5. Taiwan
          • 7.3.3.2.6. Australia
          • 7.3.3.2.7. Rest of Asia-Pacific
        • 7.3.3.3. Europe
          • 7.3.3.3.1. Germany
          • 7.3.3.3.2. France
          • 7.3.3.3.3. Italy
          • 7.3.3.3.4. United Kingdom
          • 7.3.3.3.5. Netherlands
          • 7.3.3.3.6. Rest of Europe
        • 7.3.3.4. MEA
          • 7.3.3.4.1. Middle East
          • 7.3.3.4.2. Africa
        • 7.3.3.5. North America
          • 7.3.3.5.1. United States
          • 7.3.3.5.2. Canada
          • 7.3.3.5.3. Mexico
    • 7.4. Global Adenovirus Vaccine (Price)
      • 7.4.1. Global Adenovirus Vaccine by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Adenovirus Vaccine: by Type(USD Million)
  • Table 2. Adenovirus Vaccine Type 4 Vaccine , by Region USD Million (2017-2022)
  • Table 3. Adenovirus Vaccine Type 7 Vaccine , by Region USD Million (2017-2022)
  • Table 4. Adenovirus Vaccine: by Application(USD Million)
  • Table 5. Adenovirus Vaccine Research & Academic Laboratories , by Region USD Million (2017-2022)
  • Table 6. Adenovirus Vaccine Pharmaceutical & Biotechnology Companies , by Region USD Million (2017-2022)
  • Table 7. Adenovirus Vaccine Others , by Region USD Million (2017-2022)
  • Table 8. South America Adenovirus Vaccine, by Country USD Million (2017-2022)
  • Table 9. South America Adenovirus Vaccine, by Type USD Million (2017-2022)
  • Table 10. South America Adenovirus Vaccine, by Application USD Million (2017-2022)
  • Table 11. Brazil Adenovirus Vaccine, by Type USD Million (2017-2022)
  • Table 12. Brazil Adenovirus Vaccine, by Application USD Million (2017-2022)
  • Table 13. Argentina Adenovirus Vaccine, by Type USD Million (2017-2022)
  • Table 14. Argentina Adenovirus Vaccine, by Application USD Million (2017-2022)
  • Table 15. Rest of South America Adenovirus Vaccine, by Type USD Million (2017-2022)
  • Table 16. Rest of South America Adenovirus Vaccine, by Application USD Million (2017-2022)
  • Table 17. Asia Pacific Adenovirus Vaccine, by Country USD Million (2017-2022)
  • Table 18. Asia Pacific Adenovirus Vaccine, by Type USD Million (2017-2022)
  • Table 19. Asia Pacific Adenovirus Vaccine, by Application USD Million (2017-2022)
  • Table 20. China Adenovirus Vaccine, by Type USD Million (2017-2022)
  • Table 21. China Adenovirus Vaccine, by Application USD Million (2017-2022)
  • Table 22. Japan Adenovirus Vaccine, by Type USD Million (2017-2022)
  • Table 23. Japan Adenovirus Vaccine, by Application USD Million (2017-2022)
  • Table 24. India Adenovirus Vaccine, by Type USD Million (2017-2022)
  • Table 25. India Adenovirus Vaccine, by Application USD Million (2017-2022)
  • Table 26. South Korea Adenovirus Vaccine, by Type USD Million (2017-2022)
  • Table 27. South Korea Adenovirus Vaccine, by Application USD Million (2017-2022)
  • Table 28. Taiwan Adenovirus Vaccine, by Type USD Million (2017-2022)
  • Table 29. Taiwan Adenovirus Vaccine, by Application USD Million (2017-2022)
  • Table 30. Australia Adenovirus Vaccine, by Type USD Million (2017-2022)
  • Table 31. Australia Adenovirus Vaccine, by Application USD Million (2017-2022)
  • Table 32. Rest of Asia-Pacific Adenovirus Vaccine, by Type USD Million (2017-2022)
  • Table 33. Rest of Asia-Pacific Adenovirus Vaccine, by Application USD Million (2017-2022)
  • Table 34. Europe Adenovirus Vaccine, by Country USD Million (2017-2022)
  • Table 35. Europe Adenovirus Vaccine, by Type USD Million (2017-2022)
  • Table 36. Europe Adenovirus Vaccine, by Application USD Million (2017-2022)
  • Table 37. Germany Adenovirus Vaccine, by Type USD Million (2017-2022)
  • Table 38. Germany Adenovirus Vaccine, by Application USD Million (2017-2022)
  • Table 39. France Adenovirus Vaccine, by Type USD Million (2017-2022)
  • Table 40. France Adenovirus Vaccine, by Application USD Million (2017-2022)
  • Table 41. Italy Adenovirus Vaccine, by Type USD Million (2017-2022)
  • Table 42. Italy Adenovirus Vaccine, by Application USD Million (2017-2022)
  • Table 43. United Kingdom Adenovirus Vaccine, by Type USD Million (2017-2022)
  • Table 44. United Kingdom Adenovirus Vaccine, by Application USD Million (2017-2022)
  • Table 45. Netherlands Adenovirus Vaccine, by Type USD Million (2017-2022)
  • Table 46. Netherlands Adenovirus Vaccine, by Application USD Million (2017-2022)
  • Table 47. Rest of Europe Adenovirus Vaccine, by Type USD Million (2017-2022)
  • Table 48. Rest of Europe Adenovirus Vaccine, by Application USD Million (2017-2022)
  • Table 49. MEA Adenovirus Vaccine, by Country USD Million (2017-2022)
  • Table 50. MEA Adenovirus Vaccine, by Type USD Million (2017-2022)
  • Table 51. MEA Adenovirus Vaccine, by Application USD Million (2017-2022)
  • Table 52. Middle East Adenovirus Vaccine, by Type USD Million (2017-2022)
  • Table 53. Middle East Adenovirus Vaccine, by Application USD Million (2017-2022)
  • Table 54. Africa Adenovirus Vaccine, by Type USD Million (2017-2022)
  • Table 55. Africa Adenovirus Vaccine, by Application USD Million (2017-2022)
  • Table 56. North America Adenovirus Vaccine, by Country USD Million (2017-2022)
  • Table 57. North America Adenovirus Vaccine, by Type USD Million (2017-2022)
  • Table 58. North America Adenovirus Vaccine, by Application USD Million (2017-2022)
  • Table 59. United States Adenovirus Vaccine, by Type USD Million (2017-2022)
  • Table 60. United States Adenovirus Vaccine, by Application USD Million (2017-2022)
  • Table 61. Canada Adenovirus Vaccine, by Type USD Million (2017-2022)
  • Table 62. Canada Adenovirus Vaccine, by Application USD Million (2017-2022)
  • Table 63. Mexico Adenovirus Vaccine, by Type USD Million (2017-2022)
  • Table 64. Mexico Adenovirus Vaccine, by Application USD Million (2017-2022)
  • Table 65. Adenovirus Vaccine Sales: by Type(K Units)
  • Table 66. Adenovirus Vaccine Sales Type 4 Vaccine , by Region K Units (2017-2022)
  • Table 67. Adenovirus Vaccine Sales Type 7 Vaccine , by Region K Units (2017-2022)
  • Table 68. Adenovirus Vaccine Sales: by Application(K Units)
  • Table 69. Adenovirus Vaccine Sales Research & Academic Laboratories , by Region K Units (2017-2022)
  • Table 70. Adenovirus Vaccine Sales Pharmaceutical & Biotechnology Companies , by Region K Units (2017-2022)
  • Table 71. Adenovirus Vaccine Sales Others , by Region K Units (2017-2022)
  • Table 72. South America Adenovirus Vaccine Sales, by Country K Units (2017-2022)
  • Table 73. South America Adenovirus Vaccine Sales, by Type K Units (2017-2022)
  • Table 74. South America Adenovirus Vaccine Sales, by Application K Units (2017-2022)
  • Table 75. Brazil Adenovirus Vaccine Sales, by Type K Units (2017-2022)
  • Table 76. Brazil Adenovirus Vaccine Sales, by Application K Units (2017-2022)
  • Table 77. Argentina Adenovirus Vaccine Sales, by Type K Units (2017-2022)
  • Table 78. Argentina Adenovirus Vaccine Sales, by Application K Units (2017-2022)
  • Table 79. Rest of South America Adenovirus Vaccine Sales, by Type K Units (2017-2022)
  • Table 80. Rest of South America Adenovirus Vaccine Sales, by Application K Units (2017-2022)
  • Table 81. Asia Pacific Adenovirus Vaccine Sales, by Country K Units (2017-2022)
  • Table 82. Asia Pacific Adenovirus Vaccine Sales, by Type K Units (2017-2022)
  • Table 83. Asia Pacific Adenovirus Vaccine Sales, by Application K Units (2017-2022)
  • Table 84. China Adenovirus Vaccine Sales, by Type K Units (2017-2022)
  • Table 85. China Adenovirus Vaccine Sales, by Application K Units (2017-2022)
  • Table 86. Japan Adenovirus Vaccine Sales, by Type K Units (2017-2022)
  • Table 87. Japan Adenovirus Vaccine Sales, by Application K Units (2017-2022)
  • Table 88. India Adenovirus Vaccine Sales, by Type K Units (2017-2022)
  • Table 89. India Adenovirus Vaccine Sales, by Application K Units (2017-2022)
  • Table 90. South Korea Adenovirus Vaccine Sales, by Type K Units (2017-2022)
  • Table 91. South Korea Adenovirus Vaccine Sales, by Application K Units (2017-2022)
  • Table 92. Taiwan Adenovirus Vaccine Sales, by Type K Units (2017-2022)
  • Table 93. Taiwan Adenovirus Vaccine Sales, by Application K Units (2017-2022)
  • Table 94. Australia Adenovirus Vaccine Sales, by Type K Units (2017-2022)
  • Table 95. Australia Adenovirus Vaccine Sales, by Application K Units (2017-2022)
  • Table 96. Rest of Asia-Pacific Adenovirus Vaccine Sales, by Type K Units (2017-2022)
  • Table 97. Rest of Asia-Pacific Adenovirus Vaccine Sales, by Application K Units (2017-2022)
  • Table 98. Europe Adenovirus Vaccine Sales, by Country K Units (2017-2022)
  • Table 99. Europe Adenovirus Vaccine Sales, by Type K Units (2017-2022)
  • Table 100. Europe Adenovirus Vaccine Sales, by Application K Units (2017-2022)
  • Table 101. Germany Adenovirus Vaccine Sales, by Type K Units (2017-2022)
  • Table 102. Germany Adenovirus Vaccine Sales, by Application K Units (2017-2022)
  • Table 103. France Adenovirus Vaccine Sales, by Type K Units (2017-2022)
  • Table 104. France Adenovirus Vaccine Sales, by Application K Units (2017-2022)
  • Table 105. Italy Adenovirus Vaccine Sales, by Type K Units (2017-2022)
  • Table 106. Italy Adenovirus Vaccine Sales, by Application K Units (2017-2022)
  • Table 107. United Kingdom Adenovirus Vaccine Sales, by Type K Units (2017-2022)
  • Table 108. United Kingdom Adenovirus Vaccine Sales, by Application K Units (2017-2022)
  • Table 109. Netherlands Adenovirus Vaccine Sales, by Type K Units (2017-2022)
  • Table 110. Netherlands Adenovirus Vaccine Sales, by Application K Units (2017-2022)
  • Table 111. Rest of Europe Adenovirus Vaccine Sales, by Type K Units (2017-2022)
  • Table 112. Rest of Europe Adenovirus Vaccine Sales, by Application K Units (2017-2022)
  • Table 113. MEA Adenovirus Vaccine Sales, by Country K Units (2017-2022)
  • Table 114. MEA Adenovirus Vaccine Sales, by Type K Units (2017-2022)
  • Table 115. MEA Adenovirus Vaccine Sales, by Application K Units (2017-2022)
  • Table 116. Middle East Adenovirus Vaccine Sales, by Type K Units (2017-2022)
  • Table 117. Middle East Adenovirus Vaccine Sales, by Application K Units (2017-2022)
  • Table 118. Africa Adenovirus Vaccine Sales, by Type K Units (2017-2022)
  • Table 119. Africa Adenovirus Vaccine Sales, by Application K Units (2017-2022)
  • Table 120. North America Adenovirus Vaccine Sales, by Country K Units (2017-2022)
  • Table 121. North America Adenovirus Vaccine Sales, by Type K Units (2017-2022)
  • Table 122. North America Adenovirus Vaccine Sales, by Application K Units (2017-2022)
  • Table 123. United States Adenovirus Vaccine Sales, by Type K Units (2017-2022)
  • Table 124. United States Adenovirus Vaccine Sales, by Application K Units (2017-2022)
  • Table 125. Canada Adenovirus Vaccine Sales, by Type K Units (2017-2022)
  • Table 126. Canada Adenovirus Vaccine Sales, by Application K Units (2017-2022)
  • Table 127. Mexico Adenovirus Vaccine Sales, by Type K Units (2017-2022)
  • Table 128. Mexico Adenovirus Vaccine Sales, by Application K Units (2017-2022)
  • Table 129. Adenovirus Vaccine: by Type(USD/Units)
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Adenovirus Vaccine: by Type(USD Million)
  • Table 141. Adenovirus Vaccine Type 4 Vaccine , by Region USD Million (2023-2028)
  • Table 142. Adenovirus Vaccine Type 7 Vaccine , by Region USD Million (2023-2028)
  • Table 143. Adenovirus Vaccine: by Application(USD Million)
  • Table 144. Adenovirus Vaccine Research & Academic Laboratories , by Region USD Million (2023-2028)
  • Table 145. Adenovirus Vaccine Pharmaceutical & Biotechnology Companies , by Region USD Million (2023-2028)
  • Table 146. Adenovirus Vaccine Others , by Region USD Million (2023-2028)
  • Table 147. South America Adenovirus Vaccine, by Country USD Million (2023-2028)
  • Table 148. South America Adenovirus Vaccine, by Type USD Million (2023-2028)
  • Table 149. South America Adenovirus Vaccine, by Application USD Million (2023-2028)
  • Table 150. Brazil Adenovirus Vaccine, by Type USD Million (2023-2028)
  • Table 151. Brazil Adenovirus Vaccine, by Application USD Million (2023-2028)
  • Table 152. Argentina Adenovirus Vaccine, by Type USD Million (2023-2028)
  • Table 153. Argentina Adenovirus Vaccine, by Application USD Million (2023-2028)
  • Table 154. Rest of South America Adenovirus Vaccine, by Type USD Million (2023-2028)
  • Table 155. Rest of South America Adenovirus Vaccine, by Application USD Million (2023-2028)
  • Table 156. Asia Pacific Adenovirus Vaccine, by Country USD Million (2023-2028)
  • Table 157. Asia Pacific Adenovirus Vaccine, by Type USD Million (2023-2028)
  • Table 158. Asia Pacific Adenovirus Vaccine, by Application USD Million (2023-2028)
  • Table 159. China Adenovirus Vaccine, by Type USD Million (2023-2028)
  • Table 160. China Adenovirus Vaccine, by Application USD Million (2023-2028)
  • Table 161. Japan Adenovirus Vaccine, by Type USD Million (2023-2028)
  • Table 162. Japan Adenovirus Vaccine, by Application USD Million (2023-2028)
  • Table 163. India Adenovirus Vaccine, by Type USD Million (2023-2028)
  • Table 164. India Adenovirus Vaccine, by Application USD Million (2023-2028)
  • Table 165. South Korea Adenovirus Vaccine, by Type USD Million (2023-2028)
  • Table 166. South Korea Adenovirus Vaccine, by Application USD Million (2023-2028)
  • Table 167. Taiwan Adenovirus Vaccine, by Type USD Million (2023-2028)
  • Table 168. Taiwan Adenovirus Vaccine, by Application USD Million (2023-2028)
  • Table 169. Australia Adenovirus Vaccine, by Type USD Million (2023-2028)
  • Table 170. Australia Adenovirus Vaccine, by Application USD Million (2023-2028)
  • Table 171. Rest of Asia-Pacific Adenovirus Vaccine, by Type USD Million (2023-2028)
  • Table 172. Rest of Asia-Pacific Adenovirus Vaccine, by Application USD Million (2023-2028)
  • Table 173. Europe Adenovirus Vaccine, by Country USD Million (2023-2028)
  • Table 174. Europe Adenovirus Vaccine, by Type USD Million (2023-2028)
  • Table 175. Europe Adenovirus Vaccine, by Application USD Million (2023-2028)
  • Table 176. Germany Adenovirus Vaccine, by Type USD Million (2023-2028)
  • Table 177. Germany Adenovirus Vaccine, by Application USD Million (2023-2028)
  • Table 178. France Adenovirus Vaccine, by Type USD Million (2023-2028)
  • Table 179. France Adenovirus Vaccine, by Application USD Million (2023-2028)
  • Table 180. Italy Adenovirus Vaccine, by Type USD Million (2023-2028)
  • Table 181. Italy Adenovirus Vaccine, by Application USD Million (2023-2028)
  • Table 182. United Kingdom Adenovirus Vaccine, by Type USD Million (2023-2028)
  • Table 183. United Kingdom Adenovirus Vaccine, by Application USD Million (2023-2028)
  • Table 184. Netherlands Adenovirus Vaccine, by Type USD Million (2023-2028)
  • Table 185. Netherlands Adenovirus Vaccine, by Application USD Million (2023-2028)
  • Table 186. Rest of Europe Adenovirus Vaccine, by Type USD Million (2023-2028)
  • Table 187. Rest of Europe Adenovirus Vaccine, by Application USD Million (2023-2028)
  • Table 188. MEA Adenovirus Vaccine, by Country USD Million (2023-2028)
  • Table 189. MEA Adenovirus Vaccine, by Type USD Million (2023-2028)
  • Table 190. MEA Adenovirus Vaccine, by Application USD Million (2023-2028)
  • Table 191. Middle East Adenovirus Vaccine, by Type USD Million (2023-2028)
  • Table 192. Middle East Adenovirus Vaccine, by Application USD Million (2023-2028)
  • Table 193. Africa Adenovirus Vaccine, by Type USD Million (2023-2028)
  • Table 194. Africa Adenovirus Vaccine, by Application USD Million (2023-2028)
  • Table 195. North America Adenovirus Vaccine, by Country USD Million (2023-2028)
  • Table 196. North America Adenovirus Vaccine, by Type USD Million (2023-2028)
  • Table 197. North America Adenovirus Vaccine, by Application USD Million (2023-2028)
  • Table 198. United States Adenovirus Vaccine, by Type USD Million (2023-2028)
  • Table 199. United States Adenovirus Vaccine, by Application USD Million (2023-2028)
  • Table 200. Canada Adenovirus Vaccine, by Type USD Million (2023-2028)
  • Table 201. Canada Adenovirus Vaccine, by Application USD Million (2023-2028)
  • Table 202. Mexico Adenovirus Vaccine, by Type USD Million (2023-2028)
  • Table 203. Mexico Adenovirus Vaccine, by Application USD Million (2023-2028)
  • Table 204. Adenovirus Vaccine Sales: by Type(K Units)
  • Table 205. Adenovirus Vaccine Sales Type 4 Vaccine , by Region K Units (2023-2028)
  • Table 206. Adenovirus Vaccine Sales Type 7 Vaccine , by Region K Units (2023-2028)
  • Table 207. Adenovirus Vaccine Sales: by Application(K Units)
  • Table 208. Adenovirus Vaccine Sales Research & Academic Laboratories , by Region K Units (2023-2028)
  • Table 209. Adenovirus Vaccine Sales Pharmaceutical & Biotechnology Companies , by Region K Units (2023-2028)
  • Table 210. Adenovirus Vaccine Sales Others , by Region K Units (2023-2028)
  • Table 211. South America Adenovirus Vaccine Sales, by Country K Units (2023-2028)
  • Table 212. South America Adenovirus Vaccine Sales, by Type K Units (2023-2028)
  • Table 213. South America Adenovirus Vaccine Sales, by Application K Units (2023-2028)
  • Table 214. Brazil Adenovirus Vaccine Sales, by Type K Units (2023-2028)
  • Table 215. Brazil Adenovirus Vaccine Sales, by Application K Units (2023-2028)
  • Table 216. Argentina Adenovirus Vaccine Sales, by Type K Units (2023-2028)
  • Table 217. Argentina Adenovirus Vaccine Sales, by Application K Units (2023-2028)
  • Table 218. Rest of South America Adenovirus Vaccine Sales, by Type K Units (2023-2028)
  • Table 219. Rest of South America Adenovirus Vaccine Sales, by Application K Units (2023-2028)
  • Table 220. Asia Pacific Adenovirus Vaccine Sales, by Country K Units (2023-2028)
  • Table 221. Asia Pacific Adenovirus Vaccine Sales, by Type K Units (2023-2028)
  • Table 222. Asia Pacific Adenovirus Vaccine Sales, by Application K Units (2023-2028)
  • Table 223. China Adenovirus Vaccine Sales, by Type K Units (2023-2028)
  • Table 224. China Adenovirus Vaccine Sales, by Application K Units (2023-2028)
  • Table 225. Japan Adenovirus Vaccine Sales, by Type K Units (2023-2028)
  • Table 226. Japan Adenovirus Vaccine Sales, by Application K Units (2023-2028)
  • Table 227. India Adenovirus Vaccine Sales, by Type K Units (2023-2028)
  • Table 228. India Adenovirus Vaccine Sales, by Application K Units (2023-2028)
  • Table 229. South Korea Adenovirus Vaccine Sales, by Type K Units (2023-2028)
  • Table 230. South Korea Adenovirus Vaccine Sales, by Application K Units (2023-2028)
  • Table 231. Taiwan Adenovirus Vaccine Sales, by Type K Units (2023-2028)
  • Table 232. Taiwan Adenovirus Vaccine Sales, by Application K Units (2023-2028)
  • Table 233. Australia Adenovirus Vaccine Sales, by Type K Units (2023-2028)
  • Table 234. Australia Adenovirus Vaccine Sales, by Application K Units (2023-2028)
  • Table 235. Rest of Asia-Pacific Adenovirus Vaccine Sales, by Type K Units (2023-2028)
  • Table 236. Rest of Asia-Pacific Adenovirus Vaccine Sales, by Application K Units (2023-2028)
  • Table 237. Europe Adenovirus Vaccine Sales, by Country K Units (2023-2028)
  • Table 238. Europe Adenovirus Vaccine Sales, by Type K Units (2023-2028)
  • Table 239. Europe Adenovirus Vaccine Sales, by Application K Units (2023-2028)
  • Table 240. Germany Adenovirus Vaccine Sales, by Type K Units (2023-2028)
  • Table 241. Germany Adenovirus Vaccine Sales, by Application K Units (2023-2028)
  • Table 242. France Adenovirus Vaccine Sales, by Type K Units (2023-2028)
  • Table 243. France Adenovirus Vaccine Sales, by Application K Units (2023-2028)
  • Table 244. Italy Adenovirus Vaccine Sales, by Type K Units (2023-2028)
  • Table 245. Italy Adenovirus Vaccine Sales, by Application K Units (2023-2028)
  • Table 246. United Kingdom Adenovirus Vaccine Sales, by Type K Units (2023-2028)
  • Table 247. United Kingdom Adenovirus Vaccine Sales, by Application K Units (2023-2028)
  • Table 248. Netherlands Adenovirus Vaccine Sales, by Type K Units (2023-2028)
  • Table 249. Netherlands Adenovirus Vaccine Sales, by Application K Units (2023-2028)
  • Table 250. Rest of Europe Adenovirus Vaccine Sales, by Type K Units (2023-2028)
  • Table 251. Rest of Europe Adenovirus Vaccine Sales, by Application K Units (2023-2028)
  • Table 252. MEA Adenovirus Vaccine Sales, by Country K Units (2023-2028)
  • Table 253. MEA Adenovirus Vaccine Sales, by Type K Units (2023-2028)
  • Table 254. MEA Adenovirus Vaccine Sales, by Application K Units (2023-2028)
  • Table 255. Middle East Adenovirus Vaccine Sales, by Type K Units (2023-2028)
  • Table 256. Middle East Adenovirus Vaccine Sales, by Application K Units (2023-2028)
  • Table 257. Africa Adenovirus Vaccine Sales, by Type K Units (2023-2028)
  • Table 258. Africa Adenovirus Vaccine Sales, by Application K Units (2023-2028)
  • Table 259. North America Adenovirus Vaccine Sales, by Country K Units (2023-2028)
  • Table 260. North America Adenovirus Vaccine Sales, by Type K Units (2023-2028)
  • Table 261. North America Adenovirus Vaccine Sales, by Application K Units (2023-2028)
  • Table 262. United States Adenovirus Vaccine Sales, by Type K Units (2023-2028)
  • Table 263. United States Adenovirus Vaccine Sales, by Application K Units (2023-2028)
  • Table 264. Canada Adenovirus Vaccine Sales, by Type K Units (2023-2028)
  • Table 265. Canada Adenovirus Vaccine Sales, by Application K Units (2023-2028)
  • Table 266. Mexico Adenovirus Vaccine Sales, by Type K Units (2023-2028)
  • Table 267. Mexico Adenovirus Vaccine Sales, by Application K Units (2023-2028)
  • Table 268. Adenovirus Vaccine: by Type(USD/Units)
  • Table 269. Research Programs/Design for This Report
  • Table 270. Key Data Information from Secondary Sources
  • Table 271. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Adenovirus Vaccine: by Type USD Million (2017-2022)
  • Figure 5. Global Adenovirus Vaccine: by Application USD Million (2017-2022)
  • Figure 6. South America Adenovirus Vaccine Share (%), by Country
  • Figure 7. Asia Pacific Adenovirus Vaccine Share (%), by Country
  • Figure 8. Europe Adenovirus Vaccine Share (%), by Country
  • Figure 9. MEA Adenovirus Vaccine Share (%), by Country
  • Figure 10. North America Adenovirus Vaccine Share (%), by Country
  • Figure 11. Global Adenovirus Vaccine: by Type K Units (2017-2022)
  • Figure 12. Global Adenovirus Vaccine: by Application K Units (2017-2022)
  • Figure 13. South America Adenovirus Vaccine Share (%), by Country
  • Figure 14. Asia Pacific Adenovirus Vaccine Share (%), by Country
  • Figure 15. Europe Adenovirus Vaccine Share (%), by Country
  • Figure 16. MEA Adenovirus Vaccine Share (%), by Country
  • Figure 17. North America Adenovirus Vaccine Share (%), by Country
  • Figure 18. Global Adenovirus Vaccine: by Type USD/Units (2017-2022)
  • Figure 19. Global Adenovirus Vaccine share by Players 2022 (%)
  • Figure 20. Global Adenovirus Vaccine share by Players (Top 3) 2022(%)
  • Figure 21. Global Adenovirus Vaccine share by Players (Top 5) 2022(%)
  • Figure 22. BCG Matrix for key Companies
  • Figure 23. Teva Pharmaceuticals (Isreal) Revenue, Net Income and Gross profit
  • Figure 24. Teva Pharmaceuticals (Isreal) Revenue: by Geography 2022
  • Figure 25. Barr Labs (United States) Revenue, Net Income and Gross profit
  • Figure 26. Barr Labs (United States) Revenue: by Geography 2022
  • Figure 27. Wyeth Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 28. Wyeth Laboratories (United States) Revenue: by Geography 2022
  • Figure 29. Batavia Biosciences B.V. (The Netherlands) Revenue, Net Income and Gross profit
  • Figure 30. Batavia Biosciences B.V. (The Netherlands) Revenue: by Geography 2022
  • Figure 31. BAVARIAN NORDIC (Denmark) Revenue, Net Income and Gross profit
  • Figure 32. BAVARIAN NORDIC (Denmark) Revenue: by Geography 2022
  • Figure 33. AlphaVax, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. AlphaVax, Inc. (United States) Revenue: by Geography 2022
  • Figure 35. BioNTech (Germany) Revenue, Net Income and Gross profit
  • Figure 36. BioNTech (Germany) Revenue: by Geography 2022
  • Figure 37. INOVIO (United States) Revenue, Net Income and Gross profit
  • Figure 38. INOVIO (United States) Revenue: by Geography 2022
  • Figure 39. Cansino Biologics (China) Revenue, Net Income and Gross profit
  • Figure 40. Cansino Biologics (China) Revenue: by Geography 2022
  • Figure 41. Moderna (United States) Revenue, Net Income and Gross profit
  • Figure 42. Moderna (United States) Revenue: by Geography 2022
  • Figure 43. Global Adenovirus Vaccine: by Type USD Million (2023-2028)
  • Figure 44. Global Adenovirus Vaccine: by Application USD Million (2023-2028)
  • Figure 45. South America Adenovirus Vaccine Share (%), by Country
  • Figure 46. Asia Pacific Adenovirus Vaccine Share (%), by Country
  • Figure 47. Europe Adenovirus Vaccine Share (%), by Country
  • Figure 48. MEA Adenovirus Vaccine Share (%), by Country
  • Figure 49. North America Adenovirus Vaccine Share (%), by Country
  • Figure 50. Global Adenovirus Vaccine: by Type K Units (2023-2028)
  • Figure 51. Global Adenovirus Vaccine: by Application K Units (2023-2028)
  • Figure 52. South America Adenovirus Vaccine Share (%), by Country
  • Figure 53. Asia Pacific Adenovirus Vaccine Share (%), by Country
  • Figure 54. Europe Adenovirus Vaccine Share (%), by Country
  • Figure 55. MEA Adenovirus Vaccine Share (%), by Country
  • Figure 56. North America Adenovirus Vaccine Share (%), by Country
  • Figure 57. Global Adenovirus Vaccine: by Type USD/Units (2023-2028)
List of companies from research coverage that are profiled in the study
  • Teva Pharmaceuticals (Isreal)
  • Barr Labs (United States)
  • Wyeth Laboratories (United States)
  • Batavia Biosciences B.V. (The Netherlands)
  • BAVARIAN NORDIC (Denmark)
  • AlphaVax, Inc. (United States)
  • BioNTech (Germany)
  • INOVIO (United States)
  • Cansino Biologics (China)
  • Moderna (United States)
Select User Access Type

Key Highlights of Report


May 2023 223 Pages 80 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Adenovirus Vaccine Quantitative research analysis
Adenovirus Vaccine Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Historical year: 2018-2022; Base year: 2022; Forecast period: 2023 to 2028
Companies that are profiled in Global Adenovirus Vaccine Market are Teva Pharmaceuticals (Isreal), Barr Labs (United States), Wyeth Laboratories (United States), Batavia Biosciences B.V. (The Netherlands), BAVARIAN NORDIC (Denmark), AlphaVax, Inc. (United States), BioNTech (Germany), INOVIO (United States), Cansino Biologics (China) and Moderna (United States) etc.
Research & Academic Laboratories segment in Global market to hold robust market share owing to "Growing Demand due to Use in Cancer Gene Therapies".
AMA Research predicts that United States Players will contribute to the maximum growth of Global Adenovirus Vaccine market throughout the forecasted period.

Know More About Adenovirus Vaccine Report?

Have a Query? Click Here

Other Related Reports

Allergic Rhinitis Drugs Comprehensive Study by Type (Corticosteroids, Antihistamines, Vasoconstrictors, Pratropium Bromide, Others (Leukotrienes, Cromoglycate)), Application (Non-Allergic Rhinitis, M...
$ 3650
Dental Drugs Comprehensive Study by Type (Analgesic, Anesthetics, Antibiotics, Antifungals, Antiseptics, Fluorides, Benzodiazepines, Saliva Substitutes), Mode of Administration (Injectable, Oral, Spr...
$ 3450
Clarityne Comprehensive Study by Type (Loratadine Tablet, Loratadine Capsule, Loratadine Syrup), Application (Adult Drug, Pediatric Drug), Sales Channel (Hospitals, Drug Store, Specialty Pharmacy, E-...
$ 3500
General Anesthesia Drugs Comprehensive Study by Type (Propofol, Dexmedetomidine, Sevoflurane, Desflurane, Midazolam, Others), Application (Inhalational Anesthetics, Intravenous Anesthetics), Distribu...
$ 3650
Zinc Gluconate Comprehensive Study by Application (Food, Pharmaceutical, Feed, Other), Distribution Channels (Online Pharmacies, Medical Stores, Hospital Pharmacies, Others), Dosage Form (Tablets, In...
$ 3650
Zoster Vaccine Comprehensive Study by Type (Live Vaccines, Attenuated Vaccines), Application (Herpes Zoster, Others), End Users (Hospitals, Clinic, Others) Players and Region - Global Market Outlook ...
$ 3500